🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Post Marketing Surveillance Study to Observe Safety and Effectiveness of CRYSVITA® in S. Korean Patients

Recruitingn/aAges 1 Day - anyAllKyowa Kirin Korea Co., Ltd.
NCT06202027 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The objective of this post-marketing surveillance (PMS) study is to assess the safety and effectiveness of CRYSVITA injection 10, 20, and 30mg, equivalent to in routine clinical settings

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients who have been started on CRYSVITA® in accordance with the approved label in Korea 2. Those (or his/her legal guardian) who have agreed in writing to participate in the survey. Children who have obtained a written consent of his/her legal guardian about participation in this survey. In case of pediatric patient, explain sufficiently what you think the patient can understand. In this case, the legal guardian may provide supplementary explanations of the survey. Exclusion Criteria: 1. Patients for whom Burosumab is contraindicated according local label of CRYSVITA® 2. Patients who intend to use this drug for other purposes 3. Patients who participated in pre-market clinical trials with CRYSVITA® (Consecutive investigation method ONLY) 4. Patients who have been taking this drug before the starting day of this study (Consecutive investigation method ONLY)
💊

What it tests

  • FGF23-related hypophosphataemic rickets and osteomalacia
📍

Where

13 sites
Wonju Severance Christian Hospital
Wŏnju, South Korea
Ajou University Hospital
Suwon, South Korea
Yangsan Pusan National University Hospital
Yangsan, South Korea
Chonnam National University Hospital
Gwangju, South Korea
Chungnam National University Sejong Hospital
Sejong, South Korea
Inje University Busan Paik Hospital
Busan, South Korea
Pusan National University Hospital
Busan, South Korea
Seoul National University Hospital
Seoul, South Korea

…and 5 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy